- CordenPharma Frankfurt has expanded its facility to enhance peptide development and small-scale manufacturing.
- The expansion supports Phase I and II clinical programs with state-of-the-art GMP manufacturing suites.
CordenPharma Frankfurt celebrated the expansion of its facility with a ribbon-cutting ceremony led by Dr. Michael Quirmbach, President & CEO of CordenPharma Group, and Dr. Karsten Meyenberg, Managing Director of the site. This milestone comes after a successful GMP inspection by German authorities.
The upgraded facility is designed to support early-stage peptide development projects, specifically targeting Phase I and Phase II clinical programs. It features state-of-the-art GMP manufacturing suites and enhanced capacity for peptide development and small-scale manufacturing. These upgrades aim to accelerate timelines and ensure seamless integration across CordenPharma’s network for drug development and manufacturing.
The Frankfurt facility is part of CordenPharma’s larger strategy to expand peptide manufacturing capabilities. Recent investments include a greenfield facility near Basel, Switzerland, and expanded operations at its Colorado, US site. These efforts align with the company’s commitment to supporting pharmaceutical innovators and advancing next-generation peptide therapeutics.
Overview of outsourcing trends 
